Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

KEYMAKER-U01 Understudie 01J: En undersøgelse af Pembrolizumab plus MK-1084 hos deltagere med ikke-småcellet lungekræft (NSCLC) med Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) G12C-mutationer (MK-3475-01J/KEYMAKER-U01J)

6. november 2026 opdateret af: Merck Sharp & Dohme LLC

KEYMAKER-U01 Understudie 01J: En randomiseret fase 2 paraplyundersøgelse med løbende arme af undersøgelsespræparater til første-linje behandling af deltagere med fremskreden eller metastatisk ikke-pladecelle lungekræft (NSCLC) med KRAS G12C-mutationer

Researchers want to learn if using a study medicine called MK-1084 can help treat Non-Small Cell Lung Cancer (NSCLC). MK-1084 is a type of treatment called targeted therapy for the Kirsten rat sarcoma viral oncogene homolog (KRAS) G12C gene change. The goal of this study is to learn about the safety of MK-1084 and to learn how many people have the cancer get smaller or go away during the study treatment.

Studieoversigt

Status

Rekruttering

Betingelser

Intervention / Behandling

Undersøgelsestype

Interventionel

Tilmelding (Anslået)

140

Fase

  • Fase 2

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiekontakt

Studiesteder

    • Region M. de Santiago
      • Santiago, Region M. de Santiago, Chile, 7560908
        • Rekruttering
        • Centro de Oncología de Precisión ( Site 0160)
        • Kontakt:
          • Study Coordinator
          • Telefonnummer: +56991612199
      • Santiago, Region M. de Santiago, Chile, 7500921
        • Rekruttering
        • Fundacion Arturo Lopez Perez ( Site 0167)
        • Kontakt:
          • Study Coordinator
          • Telefonnummer: 56224205098
      • Santiago, Region M. de Santiago, Chile, 8420383
        • Rekruttering
        • Bradfordhill ( Site 0168)
        • Kontakt:
          • Study Coordinator
          • Telefonnummer: +56998744662
    • Northern Savonia
      • Kuopio, Northern Savonia, Finland, 70200
        • Rekruttering
        • Kuopion Yliopistollinen Sairaala ( Site 0261)
        • Kontakt:
          • Study Coordinator
          • Telefonnummer: +35817173311
    • Pohjanmaa
      • Vaasa, Pohjanmaa, Finland, 65130
        • Rekruttering
        • Vaasan Keskussairaala ( Site 0263)
        • Kontakt:
          • Study Coordinator
          • Telefonnummer: +358405533545
    • Southwest Finland
      • Turku, Southwest Finland, Finland, 20520
        • Rekruttering
        • Turku University Hospital ( Site 0262)
        • Kontakt:
          • Study Coordinator
          • Telefonnummer: +35823138709
    • Uusimaa
      • Helsinki, Uusimaa, Finland, 00290
        • Rekruttering
        • HYKS Syöpätautien klinikka ( Site 0260)
        • Kontakt:
          • Study Coordinator
          • Telefonnummer: +358406682951
    • Florida
      • Clermont, Florida, Forenede Stater, 34711
        • Rekruttering
        • Clermont Oncology Center ( Site 0041)
        • Kontakt:
          • Study Coordinator
          • Telefonnummer: 386-538-3169
    • North Dakota
      • Fargo, North Dakota, Forenede Stater, 58102
        • Rekruttering
        • Sanford Health Roger Maris Cancer Center ( Site 0039)
        • Kontakt:
          • Study Coordinator
          • Telefonnummer: 701-234-2000
    • South Dakota
      • Sioux Falls, South Dakota, Forenede Stater, 57104
        • Rekruttering
        • Sanford Cancer Center Oncology Clinic ( Site 0038)
        • Kontakt:
          • Study Coordinator
          • Telefonnummer: 605-328-8000
    • Attica
      • Athens, Attica, Grækenland, 106 76
        • Rekruttering
        • Evangelismos General Hospital of Athens ( Site 0200)
        • Kontakt:
          • Study Coordinator
          • Telefonnummer: +302132041631
    • Overijssel
      • Deventer, Overijssel, Holland, 7416 SE
        • Rekruttering
        • Deventer Ziekenhuis ( Site 0272)
        • Kontakt:
          • Study Coordinator
          • Telefonnummer: +31570536437
    • South Holland
      • Leiden, South Holland, Holland, 2333 ZA
        • Rekruttering
        • Leids Universitair Medisch Centrum ( Site 0273)
        • Kontakt:
          • Study Coordinator
          • Telefonnummer: +31715566376
      • Central, Hong Kong, 0000
        • Rekruttering
        • Hong Kong Integrated Oncology Centre ( Site 0232)
        • Kontakt:
          • Study Coordinator
          • Telefonnummer: +85237006888
      • Hong Kong, Hong Kong
        • Rekruttering
        • Queen Mary Hospital ( Site 0230)
        • Kontakt:
          • Study Coordinator
          • Telefonnummer: +85222551727
      • Kowloon, Hong Kong
        • Rekruttering
        • Hong Kong United Oncology Centre ( Site 0231)
        • Kontakt:
          • Study Coordinator
          • Telefonnummer: +852 2386 8002
    • Lombardy
      • Milan, Lombardy, Italien, 20133
        • Rekruttering
        • Fondazione IRCCS Istituto Nazionale Dei Tumori ( Site 0175)
        • Kontakt:
          • Study Coordinator
          • Telefonnummer: 00390223903829
    • Jiangsu
      • Nanjing, Jiangsu, Kina, 210000
        • Rekruttering
        • Nanjing Drum Tower Hospital The Affiliated Hospital of Nanjing University Medical School ( Site 0318)
        • Kontakt:
          • Study Coordinator
          • Telefonnummer: +8602568182222
    • Jiangxi
      • Nanchang, Jiangxi, Kina, 330209
        • Rekruttering
        • The First affiliated hospital of Nanchang University (Xianghu campus) ( Site 0306)
        • Kontakt:
          • Study Coordinator
          • Telefonnummer: +86 791 8631 9333
    • Shanghai Municipality
      • Shanghai, Shanghai Municipality, Kina, 200032
        • Rekruttering
        • Zhongshan Hospital Fudan University ( Site 0319)
        • Kontakt:
          • Study Coordinator
          • Telefonnummer: +8615000229853
    • Sichuan
      • Chengdu, Sichuan, Kina, 610066
        • Rekruttering
        • West China Hospital, Sichuan University ( Site 0315)
        • Kontakt:
          • Study Coordinator
          • Telefonnummer: +8618980602252
    • Masovian Voivodeship
      • Warsaw, Masovian Voivodeship, Polen, 02-781
        • Rekruttering
        • Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - Panstwowy Instytut Badawczy w Warszawie ( Site 0151)
        • Kontakt:
          • Study Coordinator
          • Telefonnummer: 48 22 546 23 36
      • Seville, Spanien, 41009
        • Rekruttering
        • Hospital Universitario Virgen de la Macarena ( Site 0093)
        • Kontakt:
          • Study Coordinator
          • Telefonnummer: +34 671560092
      • Seoul, Sydkorea, 03722
        • Rekruttering
        • Severance Hospital Yonsei University Health System ( Site 0080)
        • Kontakt:
          • Study Coordinator
          • Telefonnummer: +82222280880
    • Bangkok
      • Bangkok, Bangkok, Thailand, 10300
        • Rekruttering
        • Bangkok Metropolitan Administration Medical College and Vajira Hospital ( Site 0351)
        • Kontakt:
          • Study Coordinator
          • Telefonnummer: +6622443461
      • Bangkok, Bangkok, Thailand, 10700
        • Rekruttering
        • Faculty of Medicine Siriraj Hospital ( Site 0350)
        • Kontakt:
          • Study Coordinator
          • Telefonnummer: +6624194488-9
      • Adana, Tyrkiet (Türkiye), 34010
        • Rekruttering
        • Koç Üniversitesi Hastanesi ( Site 0142)
        • Kontakt:
          • Study Coordinator
          • Telefonnummer: 08502508250-21251
      • Adana, Tyrkiet (Türkiye), 1250
        • Rekruttering
        • Baskent University Dr. Turgut Noyan Research and Training Center ( Site 0141)
        • Kontakt:
          • Study Coordinator
          • Telefonnummer: +905537766235
      • Ankara, Tyrkiet (Türkiye), 6230
        • Rekruttering
        • Hacettepe Universite Hastaneleri ( Site 0140)
        • Kontakt:
          • Study Coordinator
          • Telefonnummer: +90 312 305 50 00
      • Ankara, Tyrkiet (Türkiye), 06680
        • Rekruttering
        • Liv Hospital Ankara ( Site 0146)
        • Kontakt:
          • Study Coordinator
          • Telefonnummer: 905469299990
    • Kayseri
      • Talas, Kayseri, Tyrkiet (Türkiye), 38039
        • Rekruttering
        • Erciyes University ( Site 0145)
        • Kontakt:
          • Study Coordinator
          • Telefonnummer: 905366550924
      • Kyiv, Ukraine, 03022
        • Aktiv, ikke rekrutterende
        • VISION PARTNER Medical Centre ( Site 0135)
      • Kyiv, Ukraine, 03151
        • Rekruttering
        • LLC "MEDICAL CENTER DOBROBUT-CLINIC" ( Site 0138)
        • Kontakt:
          • Study Coordinator
          • Telefonnummer: +380671502987
    • Cherkasy Oblast
      • Cherkasy, Cherkasy Oblast, Ukraine, 18009
        • Rekruttering
        • COMMUNAL NONPROFIT ENTERPRISE CLINICAL CENTER OF ONCOLOGY, HEMATOLOGY, TRANSPLANTOLOGY AND PALLIATI ( Site 0139)
        • Kontakt:
          • Study Coordinator
          • Telefonnummer: +380472370123
    • Dnipropetrovsk Oblast
      • Kryvyi Rih, Dnipropetrovsk Oblast, Ukraine, 50000
        • Rekruttering
        • Medical Center "Mriya Med-Service"-Clinical Research Department ( Site 0465)
        • Kontakt:
          • Study Coordinator
          • Telefonnummer: +380677490687
    • Ivano-Frankivsk Oblast
      • Ivano-Frankivsk, Ivano-Frankivsk Oblast, Ukraine, 76018
        • Rekruttering
        • Communal Non-Commercial Enterprise "Prykarpatski Clinical On-Surgery department #2 ( Site 0132)
        • Kontakt:
          • Study Coordinator
          • Telefonnummer: 380978411455
    • Kirovohrad Oblast
      • Kropyvnytskyi, Kirovohrad Oblast, Ukraine, 25011
        • Rekruttering
        • Limited Liability Company Ukrainian Center of Tomotherapy-Department of Chemotherapy ( Site 0467)
        • Kontakt:
          • Study Coordinator
          • Telefonnummer: +380958718674
    • Lviv Oblast
      • Lviv, Lviv Oblast, Ukraine, 79059
        • Rekruttering
        • Lviv Territorial Medical Union Multidisciplinary Clinical Hospital ( Site 0133)
        • Kontakt:
          • Study Coordinator
          • Telefonnummer: +380677724757
    • Vinnytsia Oblast
      • Vinnitsya, Vinnytsia Oblast, Ukraine, 21029
        • Rekruttering
        • Communal Noncommercial Enterprise "Podillia Regional Oncolog-Cardiothoracic department ( Site 0131)
        • Kontakt:
          • Study Coordinator
          • Telefonnummer: 380953105783
    • Zakarpattia Oblast
      • Uzhhorod, Zakarpattia Oblast, Ukraine, 88000
        • Rekruttering
        • Uzhhorod Municipal Multidisciplinary Clinical Hospital of Uzhhorod City Council ( Site 0137)
        • Kontakt:
          • Study Coordinator
          • Telefonnummer: +380506847086

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

18 år og ældre (Voksen, Ældre voksen)

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Alle

Beskrivelse

Inclusion Criteria:

The main inclusion criteria include but are not limited to the following:

  • Has histologically or cytologically confirmed diagnosis of advanced or metastatic nonsquamous Non-Small Cell Lung Cancer (NSCLC)
  • Has tumor tissue or circulating tumor deoxyribonucleic acid (ctDNA) that demonstrates the presence of Kirsten rat sarcoma viral oncogene homolog (KRAS) G12C mutations
  • Can provide an archival tumor tissue sample or newly obtained core, incisional, excisional biopsy of a tumor lesion not previously irradiated
  • Has recovered to ≤Grade 1 or baseline from any Adverse events (AEs) due to previous anticancer therapies and/or ≤Grade 2 neuropathy and/or endocrine-related AEs adequately treated with hormone replacement
  • Has well controlled human immunodeficiency virus (HIV) on antiretroviral therapy (ART) if HIV-infected
  • Has undetectable hepatitis B (HBV) viral load and have received HBV antiviral therapy for at least 4 weeks if hepatitis B surface antigen (HBsAg) positive
  • Has undetectable hepatitis C (HCV) viral load if HCV-infected

Exclusion Criteria:

The main exclusion criteria include but are not limited to the following:

  • Has a diagnosis of small cell lung cancer or, for mixed tumors, presence of small cell elements
  • Has HIV-infection with a history of Kaposi's sarcoma and/or Multicentric Castleman's Disease
  • Has history of documented severe dry eye syndrome, severe Meibomian gland disease and/or blepharitis, or severe corneal disease that prevents/delays corneal healing
  • Has active inflammatory bowel disease requiring immunosuppressive medication or previous clear history of inflammatory bowel disease
  • Has uncontrolled, clinically significant cardiovascular disease or cerebrovascular disease, including New York Heart Association Class III or IV congestive heart failure, unstable angina, myocardial infarction, uncontrolled symptomatic arrhythmia, prolongation of corrected QT interval corrected for heart rate by Fridericia's formula (QTcF) interval to >470 ms, and/or other serious cardiovascular and cerebrovascular diseases within the 6 months preceding study intervention
  • Has received prior systemic anticancer therapy for advanced or metastatic NSCLC
  • Has received any prior immunotherapy and was discontinued from that treatment due to a Grade 3 or higher immune-related adverse event (irAE) (except endocrine disorders that can be treated with replacement therapy) or was discontinued from that treatment due to Grade 2 myocarditis or recurrent Grade 2 pneumonitis
  • Has received previous treatment with an agent targeting KRAS
  • Has received prior systemic anticancer therapy within 4 weeks or 5 half-lives (whichever is shorter) and has not recovered to grade ≤ 1 or baseline from AE associated with anticancer therapy before allocation/randomization
  • Has received radiation therapy to the lung that is >30 Gray within 6 months of start of study intervention
  • Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy (in dosing exceeding 10 mg daily of prednisone equivalent) or any other form of immunosuppressive therapy within 7 days prior to the first dose of study intervention
  • Has a known additional malignancy that is progressing or has required active treatment within the past 3 years
  • Has a known active central nervous system (CNS) metastases and/or carcinomatous meningitis
  • Has an active autoimmune disease that has required systemic treatment in the past 2 years. Replacement therapy (eg, thyroxine, insulin, or physiologic corticosteroid) is allowed
  • Has a history of (noninfectious) pneumonitis/interstitial lung disease (ILD) that required steroids, has current pneumonitis/ILD, or has suspected ILD or pneumonitis that cannot be ruled out by standard diagnostic assessments at screening
  • Has a history of stem cell/solid organ transplant
  • Has not adequately recovered from major surgery or has ongoing surgical complications

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Behandling
  • Tildeling: Randomiseret
  • Interventionel model: Parallel tildeling
  • Maskning: Enkelt

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Eksperimentel: Arm A- Pembrolizumab + MK-1084

Participants receive 400 mg of Pembrolizumab every 6 weeks and MK-1084 dose regimen.

Oral Administration

Intravenous administration

Andre navne:
  • Keytruda
  • MK-3475
Eksperimentel: Arm B- Pembrolizumab + MK-1084 + Cetuximab

Participants receive 400 mg of Pembrolizumab every 6 weeks, MK-1084 dose regimen, and Cetuximab 500 mg/m^2 every 2 weeks.

Intravenous administration

Oral Administration

Intravenous administration

Andre navne:
  • Keytruda
  • MK-3475
Eksperimentel: Arm C- Pembrolizumab + MK-1084 + sacituzumab tirumotecan (sac-TMT)

Participants receive 400 mg of Pembrolizumab every 6 weeks, MK-1084 dose regimen, and 4 mg/kg sacituzumab tirumotecan (sac-TMT) every 2 weeks.

Oral Administration

Intravenous administration

Andre navne:
  • Keytruda
  • MK-3475

Injection powder for intravenous infusion

Andre navne:
  • SKB264
  • MK-2870

Participants receive the following rescue medications, per approved product label, as premedication to study treatment to prevent hypersensitivity and/or infusion reactions: diphenhydramine (or equivalent histamine-1 [Hl] receptor antagonist), H2 receptor antagonist, acetaminophen or equivalent, dexamethasone or equivalent infusion, and granulocyte colony-stimulating factor (G-CSF). A steroid mouthwash (dexamethasone or equivalent) will be given as prophylaxis for stomatitis/oral mucositis.

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Percentage of Participants with a Dose Limiting Toxicity (DLT)
Tidsramme: Up to approximately 21 days

A DLT is defined as the occurrence of protocol-specified toxicities if assessed by the investigator to be possibly, probably, or definitely related to study intervention administration, excluding toxicities clearly not related to the drug.

Up to approximately 21 days
Percentage of Participants who Experience at Least One Adverse Event (AE)
Tidsramme: Up to approximately 84 months

An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention.

Up to approximately 84 months
Percentage of Participants who Discontinue Study Intervention Due to an AE
Tidsramme: Up to approximately 84 months

An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention.

Up to approximately 84 months
Objective Response Rate (ORR) per Response Evaluation Criteria In Solid Tumors (RECIST) 1.1 as assessed by Blinded Independent Central Review (BICR)
Tidsramme: Up to approximately 84 months

ORR is defined as the percentage of participants with Complete Response (CR: disappearance of all target lesions) or Partial Response (PR: at least a 30% decrease in the sum of diameters of target lesions) per RECIST 1.1. The percentage of participants who experience CR or PR as assessed by BICR will be presented.

Up to approximately 84 months

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Duration of Response (DOR) per RECIST 1.1 as assessed by BICR
Tidsramme: Up to approximately 84 months

For participants who demonstrate a confirmed Complete Response (CR: disappearance of all target lesions) or Partial Response (PR: at least a 30% decrease in the sum of diameters of target lesions) per RECIST 1.1, DOR is defined as the time from first documented evidence of CR or PR until progressive disease (PD) or death. Per RECIST 1.1, PD is defined as at least a 20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. The appearance of one or more new lesions is also considered PD. DOR as assessed by BICR will be presented.

Up to approximately 84 months
Progression Free Survival (PFS) per RECIST 1.1 as assessed by BICR
Tidsramme: Up to approximately 84 months

PFS is defined as the time from randomization to the first documented progressive disease (PD) or death due to any cause, whichever occurs first as assessed by Response Criteria in Solid Tumors Version 1.1 (RECIST 1.1). PD is defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of ≥5 mm. The appearance of one or more new lesions is also considered PD. PFS as assessed by BICR will be presented.

Up to approximately 84 months
Overall Survival (OS)
Tidsramme: Up to approximately 84 months

OS, defined as the time from first dose or randomization (depending on study period) to death due to any cause. OS will be presented.

Up to approximately 84 months
Area Under the Concentration-Time Curve (AUC) for MK-1084
Tidsramme: At designated timepoints (up to approximately 44 days)

Blood samples will be collected to determine the AUC of MK-1084.

At designated timepoints (up to approximately 44 days)
Maximum Concentration (Cmax) of MK-1084
Tidsramme: At designated timepoints (up to approximately 44 days)

Blood samples will be collected to estimate Cmax of MK-1084.

At designated timepoints (up to approximately 44 days)
Trough Concentration (Ctrough) of MK-1084
Tidsramme: At designated timepoints (up to approximately 84 months)

Blood samples will be collected to determine the Ctrough of MK-1084.

At designated timepoints (up to approximately 84 months)

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Sponsor

Efterforskere

  • Studieleder: Medical Director, Merck Sharp & Dohme LLC

Publikationer og nyttige links

Den person, der er ansvarlig for at indtaste oplysninger om undersøgelsen, leverer frivilligt disse publikationer. Disse kan handle om alt relateret til undersøgelsen.

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Faktiske)

19. december 2025

Primær færdiggørelse (Anslået)

15. november 2029

Studieafslutning (Anslået)

31. maj 2032

Datoer for studieregistrering

Først indsendt

20. november 2025

Først indsendt, der opfyldte QC-kriterier

20. november 2025

Først opslået (Faktiske)

28. november 2025

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

10. november 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

6. november 2026

Sidst verificeret

1. november 2026

Mere information

Begreber relateret til denne undersøgelse

Andre undersøgelses-id-numre

  • 3475-01J
  • U1111-1321-3999 (Registry Identifier: UTN)
  • 2025-521939-36-00 (Registry Identifier: EU CT)
  • 2025 (U.S. NIH-bevilling/kontrakt)

Plan for individuelle deltagerdata (IPD)

Planlægger du at dele individuelle deltagerdata (IPD)?

JA

IPD-planbeskrivelse

https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ja

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .